Scholar Rock Q2 net loss $37.9M; cash $249M; SAPPHIRE enrollment on track for Q3 2023

Scholar Rock Holding Corp

2023-Q2 EPS reported -$0.97

Net loss $37.9M in Q2 2023 vs $44.0M in Q2 2022; no revenue for either period.
Cash, equivalents & marketable securities $249M as of Jun 30, 2023; expected to fund into 2025.
Phase 3 SAPPHIRE trial enrollment completion expected Q3 2023; top-line data in 2H 2024.
36-month extension data from Phase 2 TOPAZ showed substantial sustained motor function improvement.
Clinical & biomarker update from DRAGON Part B (SRK-181) anticipated in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scholar Rock Holding Corp reported the quarter ended June 30, 2023 results: net income $37.9 million.

Period: the quarter ended June 30, 2023
Net income: $37.9 million
Result: reported results

Exact text from the filing

For the quarter ended June 30, 2023, net loss was $37.9 million compared to a net loss of $44.0 million for the quarter ended June 30, 2022. The Company did not record any revenue for either the quarter ended June 30, 2023 or June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001157523-23-001305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.